Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study…
<!-- Name:DistributionId Value:8827692 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
1b2
TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept…
Top line data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients, indicating the potential of slowing or reducing…
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of…
BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the…
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in…
BELTSVILLE, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class…
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at…
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination…
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for…
MIAMI, June 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases…
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of…
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases…
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study…
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and…
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase…
ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to…
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in…
SAN DIEGO and SUZHOU, China, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that the first patients have been dosed in a phase 1b/2 clinical…